This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Arslanian, S. A. Articles by Saad, R. Search for Related Content PubMed PubMed Citation Articles by Arslanian, S. A. Articles by Saad, R.

Metformin Therapy in Obese Adolescents with Polycystic Ovary Syndrome and Impaired Glucose Tolerance: Amelioration of Exaggerated Adrenal Response to Adrenocorticotropin with Reduction of Insulinemia/Insulin Resistance

Division of Pediatric Endocrinology, Metabolism, and Diabetes Mellitus, Children’s Hospital of Pittsburgh, Pittsburgh, Pennsylvania 15213

Address all correspondence and requests for reprints to: Silva A. Arslanian, M.D., Division of Endocrinology, Children’s Hospital of Pittsburgh, 3705 Fifth Avenue at DeSoto Street, Pittsburgh, Pennsylvania 15213. E-mail: . arslans{at}chplink.chp.edu

Abstract

Functional adrenal hyperandrogenism occurs in women with polycystic ovary syndrome (PCOS). Insulin, similar to its ovarian effect, may impact the regulation of adrenal steroidogenesis by modulating the activity of P450c17, the rate-limiting enzyme in androgen biosynthesis. We previously demonstrated that obese adolescents with PCOS are severely insulin resistant and are at heightened risk for impaired glucose tolerance and type 2 diabetes. In the present study we tested the hypothesis that metformin therapy in obese adolescents with PCOS will attenuate the adrenal steroidogenic response to ACTH, with reduction of insulin resistance/insulinemia. Fifteen adolescents with PCOS and impaired glucose tolerance received 3 months of metformin (850 mg, twice daily) therapy. Pre- and posttherapy they had oral glucose tolerance testing, ACTH stimulation test, a 3-h hyperinsulinemic (80 mU/m²·min)-euglycemic clamp to assess insulin sensitivity and a hyperglycemic clamp to assess insulin secretion.

After 3 months of metformin treatment, glucose intolerance improved, with eight subjects having normal glucose tolerance. Total and free T decreased [1.5 ± 0.2 vs. 1.0 ± 0.1 nmol/liter (P = 0.022) and 41.3 ± 8.3 vs. 22.2 ± 2.1 pmol/liter (P = 0.028), respectively]. Insulin-stimulated glucose disposal increased (21.5 ± 2.2 vs. 25.0 ± 2.2 µmol/kg·min; P = 0.041). Fasting insulin and oral glucose tolerance test insulin and glucose area under the curve decreased significantly. ACTH-stimulated increases in androstenedione, 17-hydroxyprogesterone, and 17-hydroxypregnenelone were lower after metformin treatment [2.8 ± 0.4 vs. 1.7 ± 0.3 nmol/liter (P = 0.014), 7.0 ± 0.6 vs. 5.3 ± 0.5 nmol/liter (P = 0.011), and 30.4 ± 3.7 vs. 25.7 ± 4.2 nmol/liter (P = 0.054)]. Fasting insulin correlated with the 17-hydroxypregnenelone response to ACTH stimulation (r = 0.52; P = 0.008).

In summary, metformin treatment of obese adolescents with PCOS and impaired glucose tolerance is beneficial in improving glucose tolerance and insulin sensitivity, in lowering insulinemia, and in reducing elevated androgen levels. Moreover, metformin therapy is associated with attenuation of the adrenal steroidogenic response to ACTH. Metformin therapy was well tolerated. In conclusion, double blind, placebo-controlled studies will determine whether insulin-sensitizing therapy corrects not only ovarian hyperandrogenism but also functional adrenal hyperandrogenism in adolescents with PCOS.

This article has been cited by other articles:

				J. Puurunen, T. Piltonen, P. Jaakkola, A. Ruokonen, L. Morin-Papunen, and J. S. Tapanainen Adrenal Androgen Production Capacity Remains High up to Menopause in Women with Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., June 1, 2009; 94(6): 1973 - 1978. [Abstract] [Full Text] [PDF]

				T. H. Inge, G. Miyano, J. Bean, M. Helmrath, A. Courcoulas, C. M. Harmon, M. K. Chen, K. Wilson, S. R. Daniels, V. F. Garcia, et al. Reversal of Type 2 Diabetes Mellitus and Improvements in Cardiovascular Risk Factors After Surgical Weight Loss in Adolescents Pediatrics, January 1, 2009; 123(1): 214 - 222. [Abstract] [Full Text] [PDF]

				K. E. S. Salley, E. P. Wickham, K. I. Cheang, P. A. Essah, N. W. Karjane, and J. E. Nestler POSITION STATEMENT: Glucose Intolerance in Polycystic Ovary Syndrome A Position Statement of the Androgen Excess Society J. Clin. Endocrinol. Metab., December 1, 2007; 92(12): 4546 - 4556. [Abstract] [Full Text] [PDF]

				S. Lee, N. Gungor, F. Bacha, and S. Arslanian Insulin Resistance: Link to the components of the metabolic syndrome and biomarkers of endothelial dysfunction in youth Diabetes Care, August 1, 2007; 30(8): 2091 - 2097. [Abstract] [Full Text] [PDF]

				M. Ojaniemi and M. Pugeat An adolescent with polycystic ovary syndrome Eur. J. Endocrinol., November 1, 2006; 155(suppl_1): S149 - S152. [Abstract] [Full Text] [PDF]

				V. De Leo, M.C. Musacchio, G. Morgante, P. Piomboni, and F. Petraglia Metformin treatment is effective in obese teenage girls with PCOS Hum. Reprod., September 1, 2006; 21(9): 2252 - 2256. [Abstract] [Full Text] [PDF]

				S. Srinivasan, G. R. Ambler, L. A. Baur, S. P. Garnett, M. Tepsa, F. Yap, G. M. Ward, and C. T. Cowell Randomized, Controlled Trial of Metformin for Obesity and Insulin Resistance in Children and Adolescents: Improvement in Body Composition and Fasting Insulin J. Clin. Endocrinol. Metab., June 1, 2006; 91(6): 2074 - 2080. [Abstract] [Full Text] [PDF]

				J. D. Veldhuis, J. N. Roemmich, E. J. Richmond, and C. Y. Bowers Somatotropic and Gonadotropic Axes Linkages in Infancy, Childhood, and the Puberty-Adult Transition Endocr. Rev., April 1, 2006; 27(2): 101 - 140. [Abstract] [Full Text] [PDF]

				T. Bridger, S. MacDonald, F. Baltzer, and C. Rodd Randomized Placebo-Controlled Trial of Metformin for Adolescents With Polycystic Ovary Syndrome Arch Pediatr Adolesc Med, March 1, 2006; 160(3): 241 - 246. [Abstract] [Full Text] [PDF]

				Z. T. Bloomgarden Second World Congress on the Insulin Resistance Syndrome: Mediators, pediatric insulin resistance, the polycystic ovary syndrome, and malignancy Diabetes Care, July 1, 2005; 28(7): 1821 - 1830. [Full Text] [PDF]

				M.A. Checa, A. Requena, C. Salvador, R. Tur, J. Callejo, J.J. Espinos, F. Fabregues, J. Herrero, and (Reproductive Endocrinology Interest Group of the Insulin-sensitizing agents: use in pregnancy and as therapy in polycystic ovary syndrome Hum. Reprod. Update, July 1, 2005; 11(4): 375 - 390. [Abstract] [Full Text] [PDF]

				L. Ibanez, C. Valls, M. V. Marcos, K. Ong, D. B. Dunger, and F. de Zegher Insulin Sensitization for Girls with Precocious Pubarche and with Risk for Polycystic Ovary Syndrome: Effects of Prepubertal Initiation and Postpubertal Discontinuation of Metformin Treatment J. Clin. Endocrinol. Metab., September 1, 2004; 89(9): 4331 - 4337. [Abstract] [Full Text] [PDF]

				G. Alberti, P. Zimmet, J. Shaw, Z. Bloomgarden, F. Kaufman, and M. Silink Type 2 Diabetes in the Young: The Evolving Epidemic: The International Diabetes Federation Consensus Workshop Diabetes Care, July 1, 2004; 27(7): 1798 - 1811. [Full Text] [PDF]

				D. J. Salmi, H. C. Zisser, and L. Jovanovic Screening for and Treatment of Polycystic Ovary Syndrome in Teenagers Experimental Biology and Medicine, May 1, 2004; 229(5): 369 - 377. [Abstract] [Full Text] [PDF]

				E. Vanky, K.A. Salvesen, and S.M. Carlsen Six-month treatment with low-dose dexamethasone further reduces androgen levels in PCOS women treated with diet and lifestyle advice, and metformin Hum. Reprod., March 1, 2004; 19(3): 529 - 533. [Abstract] [Full Text] [PDF]

				M. Guido, D. Romualdi, R. Suriano, M. Giuliani, B. Costantini, R. Apa, and A. Lanzone Effect of pioglitazone treatment on the adrenal androgen response to corticotrophin in obese patients with polycystic ovary syndrome Hum. Reprod., March 1, 2004; 19(3): 534 - 539. [Abstract] [Full Text] [PDF]

				M. T. Sheehan Polycystic Ovarian Syndrome: Diagnosis and Management Clin. Med. Res., February 1, 2004; 2(1): 13 - 27. [Abstract] [Full Text] [PDF]

				Z. T. Bloomgarden American Association of Clinical Endocrinologists (AACE) Consensus Conference on the Insulin Resistance Syndrome: 25-26 August 2002, Washington, DC Diabetes Care, April 1, 2003; 26(4): 1297 - 1303. [Full Text] [PDF]

				M. Freemark Pharmacologic Approaches to the Prevention of Type 2 Diabetes in High Risk Pediatric Patients J. Clin. Endocrinol. Metab., January 1, 2003; 88(1): 3 - 13. [Full Text] [PDF]

				Z. T. Bloomgarden Obesity, Hypertension, and Insulin Resistance Diabetes Care, November 1, 2002; 25(11): 2088 - 2097. [Full Text] [PDF]

				M. Li, J. F. Youngren, A. Dunaif, I. D. Goldfine, B. A. Maddux, B. B. Zhang, and J. L. Evans Decreased Insulin Receptor (IR) Autophosphorylation in Fibroblasts from Patients with PCOS: Effects of Serine Kinase Inhibitors and IR Activators J. Clin. Endocrinol. Metab., September 1, 2002; 87(9): 4088 - 4093. [Abstract] [Full Text] [PDF]